Cantargia: Two new abstracts at AACR 2025 - Redeye
Redeye comments on Cantargia's two new abstracts from the AACR meeting 2025, the first about nadunolimab’s anti-neuropathy effect and the second about a new antibody-drug conjugate targeting IL1RAP.
ANNONS
Redeye comments on Cantargia's two new abstracts from the AACR meeting 2025, the first about nadunolimab’s anti-neuropathy effect and the second about a new antibody-drug conjugate targeting IL1RAP.